Skip to content

United Therapeutics Corporation Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 4, 2026 results vs estimates

United Therapeutics Corporation · E.UTHR.NASDAQ · United States
Use symbol E.UTHR.NASDAQ in our API & Excel add-in to retrieve this data ↓
593.54
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 31.58%

United Therapeutics Corporation Forecast

United Therapeutics Corporation short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 31.6% a year, a typical one-standard-deviation range is 567.14–619.94 over a week, 539.43–647.65 over a month and 406.10–780.98 over a year. (Signals as of 1 Nov 2026.)

United Therapeutics Corporation Price Chart

MacroFinance.ai

United Therapeutics Corporation Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
United Therapeutics Corporation
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
United Therapeutics Corporation
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
United Therapeutics Corporation
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
United Therapeutics Corporation
P/E
21.85x
Stretched vs own history
QoQ +21.9%
YoY +23.7%
now 21.845416.61 low21.85 high
ⓘP/E As of 22 Nov 2026.See United Therapeutics Corporation returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
United Therapeutics Corporation
P/S
8.44x
Stretched vs own history
QoQ +13.2%
YoY +17.5%
now 8.43536.9 low8.86 high
ⓘP/S As of 22 Nov 2026.See United Therapeutics Corporation returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
United Therapeutics Corporation
P/B
4.28x
Stretched vs own history
QoQ +16.7%
YoY +25.7%
now 4.28423.23 low4.55 high
ⓘP/B As of 22 Nov 2026.See United Therapeutics Corporation returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
United Therapeutics Corporation
FCF Yield
3.2%
Weak vs own history
QoQ −30.7%
YoY −35.4%
now 3.22533.23 low5.1 high
ⓘFCF Yield As of 22 Nov 2026.See United Therapeutics Corporation returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
United Therapeutics Corporation
Earnings Yield
4.6%
Weak vs own history
QoQ −17.9%
YoY −19.2%
now 4.57764.58 low6.02 high
ⓘEarnings Yield As of 22 Nov 2026.See United Therapeutics Corporation returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
United Therapeutics Corporation
Market Cap
$26.9B
Highest in 5 years
QoQ +14.4%
YoY +19.7%
now 26887.36221,776 low28,183 high
ⓘMarket Cap As of 22 Nov 2026.See United Therapeutics Corporation returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
United Therapeutics Corporation
Current Ratio
4.61x
Mid-range vs own history
QoQ −19.5%
YoY −27.9%
now 4.61354.61 low6.6 high
ⓘCurrent Ratio As of 22 Nov 2026.See United Therapeutics Corporation returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
United Therapeutics Corporation
Quick Ratio
4.29x
Weak vs own history
QoQ −20.7%
YoY −29.4%
now 4.29014.29 low6.28 high
ⓘQuick Ratio As of 22 Nov 2026.See United Therapeutics Corporation returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
United Therapeutics Corporation
Interest Coverage
124.87x
Strong vs own history
QoQ −5.5%
YoY +80.8%
now 124.873969.07 low132.08 high
ⓘInterest Coverage As of 22 Nov 2026.See United Therapeutics Corporation returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
United Therapeutics Corporation
Piotroski F-Score
5
Weak vs own history
QoQ 0.0%
YoY −28.6%
now 55 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See United Therapeutics Corporation returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
United Therapeutics Corporation
Altman Z-Score
24.69
Strong vs own history
QoQ +19.8%
YoY +18.0%
now 24.690819.35 low24.7 high
ⓘAltman Z-Score As of 22 Nov 2026.See United Therapeutics Corporation returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  18 members-only factors: Sloan Accruals, Cash-Earnings Gap, Days Sales in Receivables Index, Gross Margin Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for United Therapeutics Corporation, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

United Therapeutics Corporation fundamentals: income statement, balance sheet & cash flow

United Therapeutics Corporation reported revenue of $3.18bn and net income of $1.33bn in FY2025, the year ended 31 December 2025 — revenue up 10.6% and net income up 11.7% on the prior year. Free cash flow was $1.04bn. These figures are as reported in the filings, not restated: 28 fiscal years and 111 quarters of history, back to December 1998. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$3.18bn
+10.6%
Net income
$1.33bn
+11.7%
Gross margin
87.92%
Free cash flow
$1.04bn
-3.7%
Net debt
-$1.52bn
Shares short (30 Oct 2026)
1.84m
3.45 days to cover
United Therapeutics Corporation income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue3,182.72,877.42,327.51,936.31,685.5
Cost of revenue384.4309.7257.5146.7122.5
Gross profit2,798.32,567.72,070.01,789.61,563.0
Research & development550.0481.0408.0322.9540.1
Operating income1,517.21,377.01,184.9979.7555.9
EBITDA1,819.01,654.41,386.81,040.3736.8
Interest expense19.542.959.332.418.6
Pre-tax income1,713.91,539.01,274.3950.6593.9
Income tax379.2343.9289.5223.3118.1
Net income1,334.71,195.1984.8727.3475.8

Download United Therapeutics Corporation fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.UTHR.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 28 fiscal years and 111 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on United Therapeutics Corporation

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

United Therapeutics Corporation Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to United Therapeutics Corporation; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How United Therapeutics Corporation’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how United Therapeutics Corporation behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About United Therapeutics Corporation (United States)

United Therapeutics Corporation is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is United Therapeutics Corporation?
United Therapeutics Corporation is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest United Therapeutics Corporation price?
The latest close is 593.54 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is United Therapeutics Corporation in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is United Therapeutics Corporation?
20-day realised volatility is 31.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.1% over a month and 4.4% over a week.
What factors affect United Therapeutics Corporation?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to United Therapeutics Corporation, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade United Therapeutics Corporation?
58 backtested tactical asset allocation strategies trade United Therapeutics Corporation through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are United Therapeutics Corporation returns analysed?
The Statistical Distribution of Returns section shows the distribution of United Therapeutics Corporation daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free United Therapeutics Corporation historical data?
In the Free historical data section of this page: the last 10 years of United Therapeutics Corporation daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free United Therapeutics Corporation historical data (last 10 years)

Browse or instantly download the last 10 years of United Therapeutics Corporation daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.UTHR.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20554.73
2026-11-19559.1
2026-11-18577.34
2026-11-17584.1
2026-11-16587.88
2026-11-13591.17
2026-11-12593.31
2026-11-11595.66
2026-11-10588.61
2026-11-09582.46
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.